CDSCO panel nod to Sun Pharma to manufacture, market antidiabetic FDC drug

Published On 2023-02-26 09:59 GMT | Update On 2023-02-26 09:59 GMT

In a significant development, pharmaceutical major, Sun Pharma has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and market the popular anti-diabetic fixed dose combination (FDC) drug comprising Dapagliflozin Propanediol Monohydrate, Sitagliptin, and Metformin Hydrochloride.

This came after the company presented the committee with the clinical report (CT) of the FDC Dapagliflozin Propanediol plus Sitagliptin plus Metformin Hydrochloride tablets.

For more details, check out the link given below:

Sun Pharma Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO panel nod to Sun Pharma to manufacture, market antidiabetic FDC drug

Similar News

Tripura MBBS admissions: 5-year service, Rs 20 lakh bond penalty

NEET PG Counselling: Advisory released on fee, training, joining policies

Calcutta HC denies NEET candidate's migration plea due to Non-receipt of OTP

SC denies relief to Fortis doctor accused of illegal kidney transplants

Rajasthan PG Medical Admissions: 2 years service, Rs 25 lakh bond required

HC Issues Notice on Demand for MBBS Fee Hike by TN Private Medical Colleges

NEET counselling 2024: MCC to hold online special stray vacancy round for vacant seats

Doctor challenges Rs 30 lakh bond penalty for leaving seat, cites mental health; HC issues notice